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Sonic hedgehog (Shh) is a morphogen regulating muscle development during embryogenesis. We have shown that the 
Shh pathway is postnatally recapitulated after injury and during regeneration of the adult skeletal muscle and regulates 
angiogenesis and myogenesis after muscle injury. Here, we demonstrate that in 18-month-old mice, there is a significant 
impairment of the upregulation of the Shh pathway that physiologically occurs in the young skeletal muscle after injury. 
Such impairment is even more pronounced in 24-month-old mice. In old animals, intramuscular therapy with a plasmid 
encoding the human Shh gene increases the regenerative capacities of the injured muscle, in terms of Myf5-positive cells, 
regenerating myofibers, and fibrosis. At the molecular level, Shh treatment increases the upregulation of the prototypi-
cal growth factors, insulin-like growth factor-1 and vascular endothelial growth factor. These data demonstrate that Shh 
increases regeneration after injury in the muscle of 24-month-old mice and suggest that the manipulation of the Shh 
pathway may be useful for the treatment of muscular diseases associated with aging.
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SONIC hedgehog (Shh) is a morphogen regulating crucial epithelial–mesenchymal interactions during embryo-
genesis (1,2). Over the last 10 years, we have demonstrated 
that the Shh pathway, which was considered generally silent 
in postnatal life, is upregulated in the adult in experimental 
models of myocardial and skeletal muscle ischemia (3–5). 
We have also shown that, in postnatal life, Shh regulates 
angiogenesis and that Shh therapy may be used to improve 
revascularization in porcine and rodent models of coro-
nary artery disease and peripheral limb ischemia (4–6). 
More recently, we have found that Shh not only regulates 
angiogenesis in the adult but also plays a functional and 
regulatory role on adult myogenesis. For instance, we have 
shown that Shh is de novo expressed after injury and dur-
ing regeneration of the adult skeletal muscle in mice and 
that Shh inhibition impairs the activation of the myogenic 
regulatory factors Myf5 and MyoD, decreases the upregula-
tion of insulin-like growth factor (IGF)-1, and reduces the 
number of muscle satellite cells (MSCs) at injured site (7). 
Also, Shh inhibition results in muscle fibrosis, increased 
inflammatory reaction, and compromised motor functional 
recovery after injury (7).
Here, we demonstrate that the activation of the Shh 
pathway in response to mechanical and toxic injury of the 
skeletal muscle is significantly impaired in old mice com-
pared with young animals. We also demonstrate that direct 
intramuscular injection of a plasmid encoding the human 
Shh gene (phShh) induces functional activation of the 
Shh signaling pathway in the aged muscle and results in 
increased regeneration and repair after injury.
Methods
Animals and Experimental Models of Muscle Injury
We used young (8–12 weeks old), 18-month-old, and 
24-month-old C57BL/6J male mice. Mice were purchased 
from Charles River Laboratories and housed in our ani-
mal facility until the age required for the experiments. 
Two injury models were used: (i) mechanical crush and 
(ii) cardiotoxin (CTX) injection of the tibialis anterior (TA) 
muscle. Injuries were carried out as previously described 
(7). In both models, contralateral TA muscles were used 
as internal controls. Muscle injuries were performed under 
anesthesia. Mice were sacrificed at various time points 
with an overdose of ketamine. All the experiments were 
approved by our Institutional Review Boards and Ethics 
Committees.
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Analysis of the Activation of the Shh Pathway in 
Response to Injury
Mechanical crush and CTX injection of the TA muscle 
were carried out unilaterally as described (7). Twenty-
five young, 18-month-old, and 24-month-old mice were 
used for each experimental model. Five mice in each 
model were sacrificed at each of the following time 
points: days 0 (before injury), 2, 4, 7, and 14. These time 
points were chosen because they encompass both early 
and late phases of muscle repair after injury and have 
been established previously (7). After sacrifice, muscles 
were harvested and the activation of the Shh pathway was 
evaluated by quantification of Shh and Gli1 messenger 
RNA (mRNA) levels by real-time reverse transcription-
PCR (RT-PCR). The primer sequences were as follows: 
Shh forward, 5′-GAGCAGACCGGCTGATGACT-3; Shh 
reverse, 5′-AGAGATGGCCAAGGCATTTAAC-3′; Gli1 
forward, 5′-TTGTCCAGCTTGGATGAAGG-3′; Gli1 
reverse, 5′-CCCAGACGGCGAGACAC-3′. One-step real-
time RT-PCR was performed using the ABI PRISM 7700 
Sequence Detection System (Applied Biosystems). Total 
RNA (2–20 ng) isolated from each muscle was added to a 
reaction mixture containing forward primer, reverse primer, 
TaqMan probe, and TaqMan One-Step RT-PCR Master Mix 
Reagents (Applied Biosystems) in a final volume of 50 μL. 
We used 18S rRNA as a stable endogenous reference gene 
to normalize the target mRNA expression. TaqMan probes 
were labeled with a fluorescent reporter dye (FAM) at the 
5′ end and a quencher dye (TAMRA) at the 3′ end. Thermal 
cycling conditions were as follows: 1 cycle of 30 minutes 
at 48°C for reverse transcription; 1 cycle of 10 minutes at 
95°C for activation of DNA polymerase; 40 cycles of 15 
seconds at 95°C for denaturation and 1 minutes at 60°C for 
annealing and extension. The expression levels of target 
gene and 18S rRNA in each sample were calculated based 
on the standard curve generated with the Mouse Universal 
Reference Total RNA (BD Biosciences Clontech). The 
expression level of target gene was then normalized by the 
expression level of 18S rRNA using TaqMan Ribosomal 
RNA Control Reagents (Applied Biosystems) to control the 
quantity of the isolated RNA. Real-time RT-PCR analyses 
were performed in duplicate.
Assessment of phShh Expression In Vivo
The phShh has been described previously (5). Also, we 
have shown already the beneficial effects of phShh therapy 
in experimental models of myocardial ischemia in rats and 
pigs and peripheral limb ischemia in mice (5,6). In these pre-
vious experiments, 200 µg phShh were able to induce func-
tional activation of the Shh pathway in the murine ischemic 
hind limb (6). Based on these data and on the relative muscle 
masses of murine hind-limb and murine TA muscle, we cal-
culated a dose equivalent of phShh (40 µg phShh) to be used 
in our experimental models of TA CTX injury. To confirm 
the ability of this treatment regimen to induce functional 
activation in the injured TA muscle of aged mice, a total of 
twenty 18-month-old mice underwent unilateral injury of the 
TA muscle by CTX injection. Immediately after injury, 10 
mice received an intramuscular injection of 40 µg phShh. 
The remaining 10 mice received an intramuscular injection 
of an equal dose of empty plasmid and were used as controls. 
Mice were sacrificed 4 and 7 days after injury and muscles 
were harvested. Expression of Gli1 was detected by real-
time RT-PCR, as described earlier. Results are expressed as 
the ratio between Gli1 expression in the treated leg versus the 
untreated leg. We also performed PCR to detect expression 
of human Shh in muscles treated with 40 µg phShh. Primers 
sequences for PCR amplification for human Shh were as 
follows: forward, 5′-GAGCAGACCGGCTGATGACT-3′; 
reverse, 5′-AGAGATGGCCAAGGCATTTAAC-3. PCR 
experimental conditions were as follows: 5 minutes at 94°C; 
1 minute at 94°C, 1 minute at 60°C, 1 minute at 72°C for 40 
cycles; 72°C for 7 minutes. Expression of mouse β-actin was 
used as housekeeping gene. PCR products were analyzed by 
2% agarose gel electrophoresis.
Quantification of Activated Muscle Satellite Cells, Newly 
Formed Myofibers, and Fibrosis
A total of sixty 24-month-old mice were used for these 
experiments. All animals underwent unilateral CTX injury 
of the TA muscle, as described earlier. Of these mice, 30 
were treated, immediately after injury, with 40 µg phShh, 
injected into the injured TA muscle. The remaining 30 
mice received an equal dose of empty plasmid, immedi-
ately after injury, by direct injection in the injured TA mus-
cle. For the analysis of activated MSCs, 10 mice in each 
treatment group were sacrificed 4  days after injury. For 
the analysis of newly formed myofibers, 10 mice in each 
treatment group were sacrificed 7  days after injury. For 
the analysis of fibrosis, 10 mice in each treatment group 
were sacrificed 14 days after injury. Activated MSCs were 
identified by positive immunostaining for Myf5, as pre-
viously described (7). To identify Shh-responding cells, 
we used a rabbit polyclonal anti-Gli1 antibody (Abcam). 
Newly formed myofibers were identified by the presence 
of centrally located nuclei, as previously described (37). 
Fibrosis was evaluated by Van Gieson staining, as previ-
ously reported (7). Calculations were done on 5 sections 
per muscle. Analyses were performed in a blinded fashion 
by two independent investigators.
Analysis of the Expression Levels of Growth Factors 
in the Injured Muscle of Old Mice Treated With phShh 
and Controls
Specimens of the TA muscles from the mice sacrificed at 
Days 4 and 7 after injury were used for assessing the protein 
levels of IGF-1 and vascular endothelial growth factor 
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(VEGF)165 by ELISA (R&D Systems), as previously 
described (3–7). Results are presented as ratio between the 
injured muscle and the contralateral side.
Statistical Analysis
All data are expressed as mean value ± SD. Statistical 
comparisons of means were performed by Student’s t test. 
A p value < .05 was considered statistically significant.
Results
Age-Dependent Impairment of the Upregulation of the Shh 
Pathway in the Skeletal Muscle in Response to Injury
Upon mechanical crush and CTX injury of the skeletal 
muscle, young mice displayed significant increase of Shh 
mRNA level (Figure 1). In both experimental models, Shh 
mRNA levels were about 10 times higher in injured mus-
cles compared with contralateral uninjured TA muscles at 
Days 2 and 4 after injury. At Day 7 after mechanical crush, 
Shh levels were about six times higher in injured muscles 
compared with the uninjured TA muscles (Figure  1a). 
Similarly, 7  days after CTX injection, Shh levels were 
about eight times higher in injured muscles compared with 
uninjured tissues (Figure 1b). At Day 14 after injury, Shh 
mRNA expression was not different in injured and control 
TA muscles (Figure 1a and b). In 18-month-old mice, the 
time course of Shh expression upon injury was similar to 
that observed in young animals, but Shh levels were sig-
nificantly lower than those observed in young mice in both 
injury models (*p < .01; Figure 1a and b). An even more 
pronounced impairment of Shh upregulation after injury 
was observed in 24-month-old mice (Figure  1a and b). 
In these mice, Shh upregulation was significantly lower 
than in 18-month-old animals at Days 2 and 4 after crush 
(*p < .01), as well as at Day 2 after CTX injury (§p < .05). 
Also, it was significantly lower than in young mice (8–12 
weeks old) at 2, 4, and 7 days after injury in both experi-
mental models (**p < .001, *p < .01).
Because Gli1 is the principal transcription factor of the 
Shh pathway, its expression constitutes evidence of func-
tional activity of the Shh pathway (3). For this reason, the 
Figure 1. Impaired activation of the Sonic hedgehog (Shh) signaling pathway in injured muscles of 18- and 24-month-old mice. Shh real-time PCR was performed 
at Days 0, 2, 4, 7, and 14 after mechanical crush (a) and cardiotoxin (CTX) injury (b) of the tibialis anterior (TA) muscle. Real-time PCR for Gli1 was performed at 
the same time points for both experimental models as well (c and d). The ratio between Shh and Gli1 mRNA levels in the injured TA muscle and the contralateral 
TA muscle increased significantly in young mice at Days 2, 4, and 7 after injury (*p < .01). In 18- and 24-month-old mice, Shh and Gli1 upregulation after both 
mechanical and toxic injury was significantly lower compared with young mice (*p < .01, **p < .001). In addition, Shh upregulation was reduced in 24-month-old 
mice compared with 18-month-old mice at Days 2 and 4 after crush (*p < .01) and at Day 2 after CTX injury (§p < .05).
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mRNA levels of Gli1 were also analyzed. We found that both 
mechanical and toxic injuries of the skeletal muscle were fol-
lowed by significant upregulation of Gli1 mRNA in young 
mice at Days 2, 4, and 7 after injury, with the highest expres-
sion level being observed at Day 4 (>8-fold increase in injured 
TA muscles compared with control TA muscles; Figure  1c 
and d). Gli1 upregulation was instead significantly impaired 
in 18-month-old mice and 24-month-old mice at 2, 4, and 
7 days after injury in both experimental models (*p < .01; 
Figure 1c and d).
Shh Gene Therapy Is Able to Induce Functional 
Activation of the Shh Pathway in the Injured Skeletal 
Muscle of Old Mice
A basic tenet of this study is that we can overexpress 
functional Shh in a controllable manner in mouse mus-
cle tissues. To prove this, we used a total of 20 old mice, 
which received an intramuscular injection of 40 μg phShh 
(n = 10) or empty plasmid (n = 10) immediately after CTX 
injury. Mice were sacrificed 4 days after injury. We found 
significantly higher expression levels of Gli1 in muscles of 
old mice injected with phShh compared with those injected 
with empty plasmid (p < .01; Figure  2a). Such levels of 
expression were similar to those observed in young mice 
at this time points after CTX injury (Figure 1d). We also 
observed strong expression of human Shh in muscles of old 
mice treated with 40 µg phShh (Figure 2b).
Shh Gene Therapy Increases the Number of Myf5-
Positive Cells in the Site of Regeneration, Enhances 
the Number of Regenerating Myofibers, and Reduces 
Fibrosis in 24-Month-Old Mice
We tested the hypothesis that, in 24-month-old mice, Shh 
gene therapy increases the regenerative capacities of the 
skeletal muscle after injury with CTX. First, we looked at 
the number of Myf5-positive cells in the site of injury. Myf5 
is a myogenic regulatory factor expressed by activated 
MSCs and represents a biological marker of regeneration. 
We found a significantly higher number of Myf5-positive 
cells in the muscles of mice treated with phShh compared 
with those of mice treated with empty plasmid (Figure 3a 
and b). In the group treated with phShh, many Myf5-postive 
cells also displayed positive staining for Gli1 (Figure 3c), 
indicating direct response of MSCs to the Shh ligand.
Upon activation, MSCs fuse to form young myotubes, which 
are characterized by centrally located nuclei. Staining with 
hematoxylin and eosin demonstrated a significantly higher 
number of fibers with centrally located nuclei in the phShh-
treated group compared with controls (Figure  4a and b). 
Finally, we assessed the extent of injury-induced mus-
cle fibrosis by performing a Van Gieson staining 14 days 
after injury. Significantly reduced extent of fibrotic tissue 
was detected in the TA muscles of mice treated with phShh 
compared with those of mice treated with the empty plas-
mid (Figure 4c and d).
Shh Gene Therapy Increases Local Expression of 
IGF-1 and VEGF165 in the Injured Skeletal Muscle of 
24-Month-Old Mice
We have previously shown that Shh regulates the 
expression of different families of angiogenic and myogenic 
growth factors (3–7). Here, we investigated whether Shh 
gene therapy has such ability also in the injured skeletal 
muscles of 24-month-old mice. For these analyses, we used 
specimens from mice sacrificed 4 and 7 days after injury. 
At both time points, the ratio between IGF-1 and VEGF165 
levels, measured by ELISA, in the injured muscle compared 
with the contralateral muscle was significantly higher in 
Figure 2. Treatment with plasmid encoding the human Shh gene (phShh) induces functional activation of the Shh pathway in the injured tibialis anterior (TA) 
muscle of 18-month-old mice. Immediately after cardiotoxin (CTX) injection, phShh (40 µg) was administered to the injured TA muscle of 18-month-old mice and 
induced significant increment of Gli1 expression compared with empty plasmid at Day 4 after injury (*p < .01) (a). Four days after injection of 40 µg phShh, expres-
sion of human Shh is detectable in the TA muscle of one 18-month-old mouse, whereas no human Shh expression may be found in the TA muscle injected with the 
empty plasmid (b).
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the phShh-treated group than in the empty plasmid-treated 
group (Figure 5).
Discussion
The repair of an injured tissue is a complex biological 
process involving the coordinated activities of tissue-resident 
and infiltrating cells in response to local and systemic signals. 
Following acute tissue injury, inflammatory cell infiltration 
and activation/proliferation of resident stem cells are the 
first line of defense to restore tissue homeostasis. However, 
many cellular and molecular mechanisms underlying 
efficient muscle repair are dysregulated in the aging muscle 
and eventually lead to impaired regeneration in response 
to injury (8–16). Indeed, the progressive incapacity of 
regeneration machinery to replace damaged muscle is a 
hallmark of age-related muscle loss or sarcopenia (16,17). 
A better understanding of impaired regenerative capacities 
represents an important first step for the development 
of therapeutic approaches. The results of our study hint 
at Shh as a novel player in the molecular mechanisms 
that underlie impaired regeneration in the aging skeletal 
muscle. The demonstration of impaired activation of the 
Shh pathway in response to injury in the skeletal muscle 
of 18- and 24-month-old mice is interesting because it is 
consistent with the concept that important mechanisms of 
muscle repair are affected by aging. The molecular and 
cellular mechanisms underlying this phenomenon remain 
to be elucidated, but this is beyond the scope of our study. 
Further investigation is needed to understand whether 
impaired activation of the Shh pathway depends on altered 
Figure 3. Treatment with plasmid encoding the human Shh gene (phShh) increases the number of activated MSCs at the injury site. In 24-month-old mice treated 
with phShh (40 µg) after cardiotoxin (CTX) injury of the tibialis anterior (TA) muscle, there is a significant higher number of activated (Myf5-positive) MSCs at the 
site of injury (244.6 ± 65.6 vs 99.7 ± 11.2 Myf5-positive cells per section, *p < .01) (a and b). Many Myf5-positive cells (green staining) are also immunopositive 
for the Shh target gene Gli1 (red/yellow staining) (c).
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function or expression of the Shh receptors or transcription 
factors, increased expression of negative modulators of the 
Shh pathway, or other mechanisms. However, our findings 
suggest that dysregulation of the Shh pathway might 
be a novel contributor to deficient muscle regeneration 
associated with aging.
In the present study, we also show that phShh is able 
to induce functional activation of the Shh pathway in the 
injured skeletal muscle of old mice, resulting in Gli1—the 
principal transcription factor of the Shh pathway—expres-
sion levels that are similar to those observed in young mice 
upon induction of injury. Our study demonstrates that 
Shh therapy activates an efficient regenerative process in 
response to injury and leads to increased number of acti-
vated MSCs and new myofibers. Not surprisingly, it also 
results in decreased fibrosis. The beneficial effects of Shh 
therapy may be due, at least in part, to direct stimulation 
of MSCs, as indicated by the fact that, in mice receiving 
Shh therapy, Myf5-positive cells express the Shh target 
gene Gli1. This is consistent with previous findings from 
our group and others, demonstrating that Shh is able to act 
on adult MSCs in vitro (7,18,19). It is also consistent with 
the fact that, in the embryo, a Gli1-binding site in the Myf5 
epaxial somite enhancer is necessary for the specification 
of epaxial muscle progenitor cells and that Gli1 interacts 
with several important myogenic pathways, such as those 
regulated by Wnt, Frizzled, Numb, and β-catenin, during 
embryonic myogenesis (20–24). In addition, it has been 
recently demonstrated that Shh induces mitogen-activated 
protein kinase/extracellular signal-regulated kinase and 
phosphoinositide 3-kinase-dependent Akt phosphorylation 
in adult myoblasts in vitro and that Shh-induced Akt phos-
phorylation is required for its promotive effects on muscle 
cell proliferation and differentiation (18).
An additional mechanism through which Shh therapy 
exerts beneficial effects in the injured muscle may be the 
upregulation of IGF-1 and VEGF165. In the last decade, 
IGF-1 has emerged as a growth factor with a remarkably 
wide range of actions and a tremendous potential as a 
therapeutic in attenuating the atrophy and frailty associ-
ated with muscle aging and diseases (25). In addition, 
IGF-1 is a protein with potent anti-apoptotic functions in 
skeletal muscle cells (26,27), thus its upregulation by Shh 
therapy might also be responsible for the reduced extent of 
fibrotic tissue observed in Shh-treated muscles. Regarding 
VEGF, it is well accepted that angiogenic cytokines have 
direct effects on muscle cells and myogenesis (6,28–32). 
In this respect, it is intriguing to note that some VEGF-
induced intracellular mechanisms, such as the phospho-
inositide 3-kinase/Akt and mitogen-activated protein 
Figure 4. Treatment with plasmid encoding the human Shh gene (phShh) increases the number of regenerating myofibers and reduces fibrosis after cardiotoxin 
(CTX) injury. Representative images of fibers with centrally located nuclei (CLN) in cross-sections of 24-month-old mice treated with phShh and empty plasmid 
(a). The number of regenerating myofibers was significantly higher in the phShh-treated group (485.5 ± 120.7 vs 123.4 ± 72.4 fibers with CLN/mm2, *p < .01) (b). 
Treatment with phShh also results in decreased percentage of fibrotic area per section (18.8% ± 6.1% vs 34.9% ± 2.3%, *p < .01) (c and d).
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kinase signaling pathways, in addition to be important 
for endothelial cell survival, migration, and proliferation, 
are also involved in muscle survival, differentiation, and 
regeneration (25,33–37).
In this scenario, it is reasonable to hypothesize that, 
in the course of muscle regeneration, Shh gene therapy 
exerts its beneficial effects both directly—on MSCs—and 
indirectly through the upregulation of growth factors such 
as IGF-1 and VEGF, which are eventually responsible for 
activating and/or enhancing myogenesis. In summary, 
our findings demonstrate that Shh therapy increases the 
regenerative capacities of the aging muscle and merits 
further investigation for its potential therapeutic utility in 
muscular diseases of the elderly.
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